KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$45.1 million.

  • Supernus Pharmaceuticals' Consolidated Net Income fell 21719.61% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.1 million, marking a year-over-year decrease of 13194.75%. This contributed to the annual value of $73.9 million for FY2024, which is 551284.19% up from last year.
  • Supernus Pharmaceuticals' Consolidated Net Income amounted to -$45.1 million in Q3 2025, which was down 21719.61% from $22.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Consolidated Net Income's 5-year high stood at $38.5 million during Q3 2024, with a 5-year trough of -$45.1 million in Q3 2025.
  • Its 5-year average for Consolidated Net Income is $8.1 million, with a median of $7.8 million in 2022.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first surged by 250652.96% in 2024, then plummeted by 964112.9% in 2025.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Consolidated Net Income stood at $2.4 million in 2021, then skyrocketed by 943.45% to $25.5 million in 2022, then plummeted by 95.39% to $1.2 million in 2023, then skyrocketed by 1208.68% to $15.4 million in 2024, then tumbled by 393.41% to -$45.1 million in 2025.
  • Its Consolidated Net Income stands at -$45.1 million for Q3 2025, versus $22.5 million for Q2 2025 and -$11.8 million for Q1 2025.